Advertisement
Advertisement
ALLO
Allogene Therapeutics Inc
2.11
USD+0.035
+1.69%
Dec 18, 13:27 UTC -5
Open
Allogene Therapeutics Inc Profile
About
Info & Links
CEO
David Chang
Headquarters
SOUTH SAN FRANCISCO, CA 94080, UNITED STATES
Industry
Sector
Website
Auditor
Ernst & Young LLP
Share holders
68
Employees
233
Allogene Therapeutics Inc Statistics
Valuation Measures
Market Capitalization2
441.36M
Enterprise Value
390.12M
Enterprise Value/EBITDA(ttm)
-1.33
Price to Earnings Ratio(ttm)
--
Price to Sales(ttm)
3.05K
Price to Book(mrq)
0.85
Price to Cash(ytd)
--
Profitability
Gross Margin(ttm)
50.00%
Operating Margin(ttm)
-212951.53%
Profit Margin(ttm)
-175980.33%
Return on Equity(ttm)
-52.13%
Return on Invested Capital(ttm)
-58.01%
Return on Assets(ttm)
-41.29%
Income Statement
Revenue(ttm)
43.00K
Revenue Per Share(ttm)
0.00
Gross Profit(ttm)
43.00K
EBITDA(ttm)3
-293.93M
Net Income Available to Common(ttm)
-283.43M
Diluted EPS(ttm)
-1.56
Share Statistics
Beta (5Y Monthly)
0.83
52-Week Change
-17.77%
S&P 500 52-Week Change
27.84%
S&P 500 Member
Yes
Stock Optionable
Yes
Total Shares Outstanding1
209.67M
Dividend Yield
0.00%
Float4
158.72M
% Held by Insiders
24.30%
% Held by Institutions
83.63%
Balance Sheet
Total Cash(mrq)
291.56M
Total Cash Per Share(mrq)
1.39
Total Debt(mrq)
0.00
Total Debt/Equity(mrq)
0.00%
Current Ratio(mrq)
9.35%
Quick Ratio(mrq)
9.35%
Book Value Per Share(mrq)
2.21
Cash Flow
Operating Cash Flow Per Share(ytd)
-0.78
Free Cash Flow(ytd)
-164.04M
Table Key
mrq = Most Recent Quarter
ttm = Trailing Twelve Months
ytd = Year To Date
Footnotes
Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.
- 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
- 2 Market Cap is calculated using total shares outstanding and the most recent share price.
- 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
- 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement